ARQT News and Press, Arcutis Biotherapeutics Inc. From 09/15/20

WESTLAKE VILLAGE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-derma...

Progression to Phase 3 clinical trials represents significant acceleration of atopic dermatitis development program Previously reported data demonstrated evidence that roflumilast cream provided symptomatic improvement and a favorable tolerability profile Roflumilast cream is a novel PD...

Arcutis Biotherapeutics (NASDAQ: ARQT ) : Q2 GAAP EPS of -$0.94 misses by $0.11 . More news on: Arcutis Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Robust pipeline anticipated to deliver two Phase 3 and four Phase 2 data events in 2020 and 2021 Arcutis currently expects no impact to its previously disclosed clinical timelines due to COVID-19 Arcutis development programs address dermatological diseases impacting over 20 million pati...

WESTLAKE VILLAGE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermat...

WESTLAKE VILLAGE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermat...

Immunic announced positive top line data for IMU-838 Immunic Inc. ( IMUX ) announced top line data from Phase EMPhASIS trial of lead drug candidate, IMU-838, aimed at patients with relapsing-remitting multiple sclerosis or RRMS. The company reported that the trial achieved all its primar...

Data demonstrate potential “Best in Class” topical PDE4 inhibitor roflumilast significantly improves signs and symptoms of chronic plaque psoriasis Phase 3 topline data anticipated first half of 2021 WESTLAKE VILLAGE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Bi...

Arcutis Biotherapeutics ( ARQT -0.5% ) has announced preliminary results for the first cohort of its ongoing Phase 2 long-term safety study evaluating topical roflumilast cream 0.3% (ARQ-151), for  plaque psoriasis. More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks ne...

Once-daily roflumilast demonstrated favorable safety and tolerability over 52 to 64 weeks of treatment At 52 to 64 weeks of treatment, 44% of subjects had attained an IGA of clear or almost clear Preliminary data further support the potential of roflumilast as a novel, once-daily, chron...